A Molecular and Preclinical Comparison of the PD-1 targeted T cell Checkpoint Inhibitors Nivolumab and Pembrolizumab
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Fessas, P
Lee, H
Ikemizu, S
Janowitz, T
Abstract
T cell checkpoint inhibition has a profound impact on cancer care and the two Programmed cell death protein 1 (PD-1) targeted antibodies nivolumab and pembrolizumab have been leading this therapeutic revolution. Their clinical comparability is a highly relevant topic of discussion, but to a significant degree is a consequence of their molecular properties. Here we provide a molecular, preclinical, and early clinical comparison of the two antibodies, based on the available data and recent literature. We acknowledge the limitations of such comparisons, but suggest that based on the available data, differences in clinical trial outcomes between nivolumab and pembrolizumab are more likely drug-independent than drug-dependent.
Description
Keywords
Nivolumab, Pembrolizumab, PD-1, T-cell checkpoint
Journal Title
Seminars in Oncology
Conference Name
Journal ISSN
0093-7754
1532-8708
1532-8708
Volume Title
44
Publisher
Elsevier
Publisher DOI
Sponsorship
Wellcome Trust Translational Medicine and Therapeutics Grant
RJAG/076